Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Oct 04, 2023 7:54am
October is a busy month ...
Good or Bad ... October is a busy month. It would be nice if we can get a positive ruling - followed by the start of PK/PD and then followed by a new molecule introduction. That would pretty much
...more
(47)
•••
TriumphSpitSix
X
View Profile
View Bullboard History
Comment by
TriumphSpitSix
on Oct 03, 2023 5:37pm
RE:Nice Try davgro
Imagine thinking there's only one Antibe investor with negative sentiment about the company. If I were to buy more, which will only happen if it dumps to the teens, it would only be to DCA this
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Oct 03, 2023 2:09pm
Nice Try davgro
ATE is close to it's 52 week low now and at a support level it has already bounced off of several times. therefore tax loss selling is not a factor the big players have not yet entered the
...more
(47)
•••
TriumphSpitSix
X
View Profile
View Bullboard History
Comment by
TriumphSpitSix
on Oct 03, 2023 2:06pm
RE:No Rush to Pickup ATE Shares, Tax Loss Selling Coming
100%. ATE has been a dog all year and will dump into year end tax loss season.
(47)
•••
TriumphSpitSix
X
View Profile
View Bullboard History
Comment by
TriumphSpitSix
on Oct 03, 2023 2:03pm
RE:* Correction
Irrelevant in any event. Point and ALX are oncology focused. They also perform.
(47)
•••
TriumphSpitSix
X
View Profile
View Bullboard History
Comment by
TriumphSpitSix
on Oct 03, 2023 2:01pm
RE:Here is what a possitive P2
Positive P2 results... nothing we would know anything about here at Antibe.
(450)
•••
davgro
X
View Profile
View Bullboard History
Post by
davgro
on Oct 03, 2023 1:07pm
Investors Avoiding "Risk-On" Stocks like ATE
RBC Capital Markets said recently that very few investors are currently looking to get aggressive in more "risk-on" stocks like clinical-stage biotech companies. Unlike Healthcare
...more
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Oct 03, 2023 1:06pm
Picked Up
another 3k @47 on the dip. maybe the same person from last week still selling? so i have picked up 15k in the last 10 days all @50 cents and lower, i will be buying more on the dips up to
...more
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Oct 03, 2023 12:33pm
* Correction
elililly buys out (PNT) point bio pharma not (ALX)
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Oct 03, 2023 12:06pm
Healthcare and Pharma Stocks
are the best place to be in a slowing economy according to the experts. just a matter of time before we get some nibbles going into yearend. and then the big fish start biting early 2024
...more
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Oct 03, 2023 10:22am
(PNT) point bio pharma
this morning elililly announces a buyout of ALX. yesterday ALX closes @ $6.68 this morning ALX is trading @ $12.38 or 85.19%. this is what could happen to ATE if all goes well in 2024 when bayer
...more
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Oct 03, 2023 10:08am
Here is what a possitive P2
result can do to a stock. yesterday ALX Oncology closed @ $4.81 this morning on news the stock was up as high as $8.27 currently still up over 50%. our turn is coming in 2024 do not miss
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 30, 2023 12:37pm
RE:RE:Today's ATE Announcement was a Zero News Event
Just to add Benedictus ... There are dilutive and non-dilutive methods to get there. There is partnering, warrants and share issue. And when I say partnering, not just talking about the obvious
...more
(162)
•••
Benedictus
X
View Profile
View Bullboard History
Comment by
Benedictus
on Sep 30, 2023 12:03am
RE:Today's ATE Announcement was a Zero News Event
I will happily take a series of NR's in which all they announce is that they continue to stay on time. This AME debacle and lengthy reformulation delay has cost us investors immensely and I don
...more
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 29, 2023 2:33pm
The cure
for a low stock price is a low stock price, at some point investors will buy it up. with eveyday that passes the stock becomes more bullish. no one in this stock is a day trader like davgro we are
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >